Digital Health Works Insights
Selling in the American Medical Market
How medtech companies should prepare before entering the US market
The American medical market can look deceptively simple from the outside. It is large, innovative, and full of hospitals, specialists, distributors, and strategic partners. But size is not the same as accessibility. A product can be clinically interesting and still fail to reach the right buyer, the right budget owner, or the right institutional pathway.
Selling in the American medical market starts with a hard commercial question: who can buy this, why would they buy now, and what internal process must they survive before they can say yes?
For medical device, SaMD, and digital health companies, this means US market entry is not just a launch campaign. It is a system for turning clinical value into institutional action.
The first mistake: treating the US as one market
The United States is not one healthcare market. It is a set of overlapping purchasing environments: academic medical centers, integrated delivery networks, community hospitals, specialty clinics, ambulatory surgery centers, imaging centers, physician groups, payers, employer health programs, distributors, and strategic channel partners.
Each environment has a different buying logic. A hospital may evaluate risk, integration, budget impact, and committee approval. A specialty clinic may care more about throughput, reimbursement, referral growth, or staff burden. A distributor may care about margin, training complexity, customer support, and whether the product fits the rep's existing call pattern.
This is why a generic US sales list is rarely enough. You need an account thesis.
Build the account thesis before the outreach list
A useful account thesis defines which accounts should care first and why. It should connect the product's value to a buying context where the pain is acute, the budget is reachable, and the adoption burden is realistic.
For example, an AI-enabled diagnostic tool may be relevant across multiple settings, but the first commercial accounts may not be the largest hospitals. They may be sites with a measurable throughput constraint, a known reimbursement pathway, a service line leader under pressure, or a strategic need to differentiate.
The goal is not to contact everyone. The goal is to find accounts where the product can become a business case.
Map the buying committee, not only the clinical champion
Clinical champions matter. They can explain unmet need, create internal urgency, and help interpret workflow. But in the American medical market, the champion is often only one part of the buying process.
A practical buyer map should identify:
- The clinical user who experiences the problem.
- The economic buyer who owns the budget or margin impact.
- The operational owner who must implement the change.
- The IT or security stakeholder who can delay deployment.
- The procurement or value analysis group that formalizes the purchase.
- The executive sponsor who can keep the project alive when priorities compete.
If you only sell to the visible user, you may win enthusiasm and still lose the purchase.
Use commercial intelligence with judgment
Commercial intelligence platforms can help identify relevant physicians, facilities, referral patterns, procedure volumes, research activity, and institutional signals. These tools are valuable because they reduce the randomness of early outreach.
But data is only useful when it is connected to a commercial hypothesis. A list of high-volume physicians is not the same as a sales strategy. A list of hospitals is not the same as an adoption pathway.
The question is: what signal suggests this account has the problem, the authority, the economics, and the urgency to act?
Translate clinical benefit into an institutional reason to buy
US healthcare buyers often need value expressed in several languages at once. Clinical benefit matters, but the purchase may also require a case for cost avoidance, operational efficiency, risk reduction, throughput, revenue capture, patient access, staff burden, or compliance.
Before entering the market, build a value story that can be used across the buying committee. The same product may need a different narrative for a physician, service line leader, hospital CFO, procurement team, and distributor partner.
This is especially important for digital health and healthcare software, where the institution may ask whether the tool creates measurable economic value or simply adds another implementation burden.
Prepare for procurement before the first serious conversation
Procurement is not an administrative afterthought. It is part of the sales process.
US hospitals and health systems commonly require vendor onboarding, security review, legal review, insurance documentation, service-level commitments, contracting terms, implementation plans, support processes, and sometimes value analysis committee review.
If those materials are improvised after a verbal yes, the deal slows down and confidence erodes. A prepared medtech sales motion should include reusable answers for the predictable questions.
Distributor sales requires a sell-through story
For companies considering distributors or manufacturer's sales representatives, the sales story must work for the channel as well as the customer.
Distributors ask practical questions:
- Does this product fit the accounts they already serve?
- Can the rep explain the value quickly?
- Is the margin worth the effort?
- How much training and support will be required?
- What objections will the rep face?
- Does the product create a repeatable opportunity or a one-off sale?
If a distributor cannot explain the product, defend the economics, and see a path to repeatable revenue, the relationship may not produce meaningful sales activity.
What to prepare before US market entry
A credible US market entry plan should include:
- A prioritized account thesis by setting, specialty, and buying context.
- A stakeholder map for the target buying process.
- Evidence and economic claims matched to each stakeholder.
- A procurement packet and standard security/legal responses.
- A pricing model aligned with how the buyer budgets.
- A distributor or direct-sales channel strategy.
- A sales enablement package that makes the story repeatable.
- A clear definition of what qualifies an opportunity.
The companies that do this work early move faster because they are not discovering the buying process one stalled deal at a time.
The practical test
Before selling in the American medical market, ask one simple question:
Can we name the account type, the buyer, the budget logic, the evidence story, the procurement pathway, and the sales motion that should produce the first invoice?
If the answer is no, the company may not be ready for US sales. It may be ready for market discovery, partner development, or value strategy first.
That is not a delay. It is how a medtech company avoids wasting its first market conversations on an offer the institution cannot yet buy.
Read this article on Digital Health Works